Development and Feasibility of a Nurse-led Person-centered Education Program (PsoEd)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05715190|
Recruitment Status : Not yet recruiting
First Posted : February 6, 2023
Last Update Posted : February 8, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Background Psoriasis is a chronic inflammatory skin disease causing reduced quality of life. Psoriasis patients are often insufficiently informed about their disease with its treatment possibilities leading to non-adherence of treatment resulting in unsatisfactory patient outcomes. We therefore propose to develop an educational intervention for psoriasis patients; evaluate the feasibility of implementing it in a nurse-led psoriasis-outpatient clinic and compare the psoriasis percentage reduction, quality of life, health literacy and patient benefit, between patients receiving this educational intervention and those receiving standard care.
Method/Design We first will develop an evidence-based educational intervention in collaboration with an expert panel and second will conduct a randomized controlled feasibility study in a psoriasis outpatient clinic in Western Switzerland. Twenty eligible patients with psoriasis will be randomized to receive either a multidisciplinary education and usual care or only usual care, for 6 weeks. Data will be analyzed using R conducting linear models allowing us to assess the impact of the intervention on psoriasis reduction and other secondary outcomes of interest, once controlled for reliable socio-economic cofounding factors.
Discussion This trial will investigate the feasibility of the elaborated nurse-led education and the planed randomized controlled trial. In this study, we will elaborate and provide an informational brochure with information concerning psoriasis in addition to a nurse-led oral educational program in addition to medical standard care. We expect that this nurse-led person-centered intervention will contribute to enhanced education with a higher functioning, better self-efficacy and improved quality of life, better disease knowledge with a better adherence to the medication protocol. The results will further inform the final design of a subsequent large-scale randomized controlled trial, which will examine the effectiveness of this educational intervention. Additionally, through this study the role of the nursing profession and its research will be strengthened in assuring that the voice of individuals, families and communities are incorporated into design and operations of clinical health systems by eliminating gaps and disparities in health care.
|Condition or disease||Intervention/treatment||Phase|
|Self-Management Behavior Patient Empowerment||Other: Education||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Single (Outcomes Assessor)|
|Primary Purpose:||Health Services Research|
|Official Title:||Development and Feasibility of a Nurse-led Person-centered Education Program on Percentage Reduction of Psoriasis in Persons With Psoriasis: a Pilot Study|
|Estimated Study Start Date :||May 1, 2023|
|Estimated Primary Completion Date :||October 31, 2023|
|Estimated Study Completion Date :||December 31, 2023|
No Intervention: Control
Visiting the medical psoriasis outpatient clinic. Receiving a medical consultation, phototherapy and methotrexate treatment.
Usual care as described for the CG will also be provided to the IG (visit to the outpatient clinic as prescribed by the physician). Psoriasis plaque measurement, psoriasis care and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by a multidisciplinary nurse-led educational program
Education- topics of the sessions are the following:
- percentage reduction of psoriasi [ Time Frame: 6 weeks ]percentage reduction of psoriasis using the PASI (Psoriasis Area and Severity Index) score. The intensity of redness, thickness, and scaling of the psoriasis is assessed as none (0), mild (1), moderate (2), severe (3), or very severe (4).
- Health Literacy [ Time Frame: 6 weeks ]French version of the Health Literacy Survey European Questionnaire (HLS-EU-Q). scoring: 0 represented the lowest health literacy and 50 the highest health literacy
- Patient benefit [ Time Frame: 6 weeks ]patient benefit index short form (PBI-S) identifying patient needs by measuring the patient-relevant benefit of treatment, Patients with PBI-S ≥ 1 are considered having at least minimum patient-relevant treatment benefit
- Life Quality Index [ Time Frame: 6 weeks ]French version of the Dermatology Life Quality Index (DLQI) questionnaire
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Diagnosed cutaneous psoriasis, regardless of the stage of the disease and treatment type (systemic and/or topic, and/or puva therapy)
- Age over 18 years
- Proficiency in the French language
- Valid informed consent is not or cannot be given
- Patients unable to follow the 6-session therapeutic education program
- Patients currently engaged in any other therapeutic education program
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05715190
|Contact: Sebastian Probst, Prof||+41 22 558 50 email@example.com|
|Centre hospitalier universitaire vaudois|
|Lausanne, VD, Switzerland, 1005|
|Principal Investigator:||Sebastian E Probst, Prof||University of Applied Sciences and Arts Western Switzerland|
|Responsible Party:||Sebastian Probst, Full Professor of Tissue Viability and Wound Care, School of Health Sciences Geneva|
|Other Study ID Numbers:||
|First Posted:||February 6, 2023 Key Record Dates|
|Last Update Posted:||February 8, 2023|
|Last Verified:||February 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Plan Description:||Open data source, Yareta|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|